Y-Mabs Therapeutics Stock Price, News & Analysis

Y-mAbs Therapeutics announced that Dr. Shakeel Modak will present results from a trial of naxitamab-based chemoimmunotherapy for high-risk neuroblastoma at the ASCO Annual Meeting from June 3-7, 2022. The trial focused on patients with chemoresistant disease, showing a 30.6% objective response rate in the MSK phase 2 trial, with significant responses in heavily pre-treated patients. The treatment showed manageable toxicity, with no unexpected severe side effects. Y-mAbs is advancing its antibody-based therapeutics in cancer treatment.

Y-mAbs Therapeutics reported a 9% sequential revenue increase to $10.5 million for Q1 2022, driven by DANYELZA® sales. The Company anticipates full-year DANYELZA revenues between $45 million and $50 million. Y-mAbs maintains a solid cash position with $156.7 million as of March 31, 2022, expected to fund operations through mid-2024. However, the Company posted a net loss of $28.1 million for the quarter, a decline from net income of $33.4 million in Q1 2021, primarily due to a one-time gain from a prior sale.

Y-mAbs Therapeutics announced it will report its financial results for Q1 2022 on May 9, 2022, after U.S. market close. A conference call is scheduled for May 10, 2022, at 9 a.m. ET with executives including Thomas Gad, Bo Kruse, and Sue Smith. The company is involved in developing antibody-based cancer therapies, with one FDA-approved product, DANYELZA®, and another candidate, omburtamab, in the registration stage. For more information, investors can join the conference call using specific access numbers and a provided webcast link.

Y-mAbs Therapeutics announces significant management changes, with Dr. Claus Moller stepping down as CEO and Board Member. Thomas Gad, the Founder and Chairman, assumes the role of Interim CEO while Dr. Jim Healy is appointed as Chairman. The company reported first-quarter 2022 revenues of $10.5 million, a 9% increase sequentially, and provided revenue guidance of $45-$50 million for the year. As of March 31, 2022, Y-mAbs has $156.7 million in cash, ensuring funding until mid-2024, amidst ongoing regulatory review of their product omburtamab.

Y-mAbs Therapeutics (Nasdaq: YMAB) announced a poster presentation at the AACR Annual Meeting 2022 in New Orleans, showcasing preclinical data on its GD2 SADA construct. The SADA technology, licensed from Memorial Sloan Kettering and MIT, enhances tumor antigen binding and anti-tumor responses. Y-mAbs is focused on antibody-based cancer therapies and has one FDA-approved product, DANYELZA, aimed at GD2-expressing tumors, and another candidate, omburtamab, targeting B7-H3-expressing tumors.

Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) has resubmitted its Biologics License Application (BLA) for ¹³¹I-omburtamab to the FDA as of March 31, 2022. This investigational monoclonal antibody targets B7-H3 in pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. The submission is informed by pivotal Phase 2 study results, expected to be published later this year. Y-mAbs aims to meet a critical medical need, as there are currently no effective treatments beyond surgery and radiotherapy for these patients.

Y-mAbs Therapeutics, Inc. (YMAB) announced significant business updates in its recent press release. The company completed a pre-BLA meeting with the FDA and plans to resubmit the BLA for omburtamab by Q1 2022. DANYELZA revenue reached $32.9 million in its first year, reflecting successful market adoption. Y-mAbs reported $34.9 million in net revenue for 2021, with a gross margin of 93%. However, the company incurred a net loss of $55.3 million for the year. Y-mAbs maintains a solid cash position of $181.6 million, ensuring operational runway through 2023.

Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) will report its financial results for the year ending December 31, 2021, on February 24, 2022, after market close. Following this, a conference call will occur on February 25, 2022, at 9 a.m. ET featuring key executives including Thomas Gad and Dr. Claus Moller. Y-mAbs focuses on antibody-based cancer treatments, with FDA-approved DANYELZA® and its registration-stage candidate omburtamab targeting specific tumor markers. The company utilizes advanced platforms for its product pipeline.

Y-mAbs Therapeutics (YMAB) announced a successful pre-BLA meeting with the FDA for omburtamab, aimed at treating CNS/leptomeningeal metastases from neuroblastoma. The company plans to resubmit the Biologics License Application by Q1 2022. A study at Memorial Sloan Kettering showed patients had a median survival of 50 months, with complete clinical data to be included in the BLA. Y-mAbs emphasizes the drug's potential to fulfill a critical medical need in pediatric oncology.